切换至 "中华医学电子期刊资源库"

中华肺部疾病杂志(电子版) ›› 2025, Vol. 18 ›› Issue (01) : 161 -164. doi: 10.3877/cma.j.issn.1674-6902.2025.01.029

短篇论著

肺淋巴上皮样癌肺叶切除与亚肺叶切除临床疗效分析
邓岭威1, 吴玲玲2, 李辉3, 张福伟3, 廖雅柔1, 王飞4   
  1. 1. 516000 惠州,惠州市第六人民医院胸外科
    2. 528000 佛山,佛山市第一人民医院胸外科
    3. 5100004 广州,南方医科大学珠江医院胸外科
    4. 528000 佛山,广东省佛山市中医院胸外乳腺科
  • 收稿日期:2024-11-26 出版日期:2025-02-25

Clinical effect of lobectomy and sublobectomy for lung lymphoepithelioid carcinoma

Lingwei Deng, Lingling Wu, Hui Li, Fuwei Zhang, Yarou Liao, Fei Wang   

  • Received:2024-11-26 Published:2025-02-25
引用本文:

邓岭威, 吴玲玲, 李辉, 张福伟, 廖雅柔, 王飞. 肺淋巴上皮样癌肺叶切除与亚肺叶切除临床疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2025, 18(01): 161-164.

Lingwei Deng, Lingling Wu, Hui Li, Fuwei Zhang, Yarou Liao, Fei Wang. Clinical effect of lobectomy and sublobectomy for lung lymphoepithelioid carcinoma[J/OL]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(01): 161-164.

表1 两组肺淋巴上皮瘤样癌患者临床资料结果比较[n(%)]
临床资料 观察组( =7) 对照组( =12) χ
性 别 3.328 0.068
 男 3(42.86) 8(66.67)
 女 4(57.14) 4(33.33)
术前TNM 分期 0.338 0.561
 Ⅰ期 4(57.14) 8(66.67)
 Ⅱ期 2(28.57) 4(33.33)
 Ⅲ期 1(14.28) 0(0.00)
术后TNM 分期 0.140 0.707
 Ⅰ期 5(71.43) 8(66.67)
 Ⅱ期 1(14.28) 3(25.00)
 Ⅲ期 1(14.28) 1(8.33)
 Ⅳ期 0(0.00) 0(0.00)
外周型肿瘤 0.069 0.792
 是 6(85.71) 10(83.33)
 否 1(14.28) 2(16.67)
吸烟史 2(28.57) 6(50.00) 2.536 0.011
鼻咽癌病史 1(14.28) 1(8.33) 1.409 0.235
免疫治疗 0(0.00) 2(16.67) 1.606 0.205
化疗方案
 紫杉醇+铂类 1(14.28) 2(16.67) 0.458 0.498
 多西他赛+铂类 0(0.00) 1(8.33) 0.211 0.646
 吉西他滨+铂类 1(14.28) 1(8.33) 0.000 0.980
 培美曲塞+铂类 0(0.00) 1(8.33) 1.28 0.258
培美曲塞 0(0.00) 0(0.00)
未化疗 5(71.43) 7(58.33) 1.928 0.165
化疗周期
 4 周期 2(28.57) 4(33.33) 0.880 0.348
 6 周期 0(0.00) 1(8.33) 1.28 0.258
 复发 2(28.57) 3(25.00) 0.614 0.433
预后 1.941 0.164
 生存者 6(85.71) 11(91.67)
 死亡者 1(14.28) 1(8.33)
图1 肺淋巴上皮瘤样癌患者术后Kaplan-Meier 生存曲线
图2 典型肺淋巴上皮瘤样癌影像学表现 A:患者,女,50 岁,右肺下叶显示软组织肿块,约30 mm×27 mm×35 mm,病灶形态不规则见分叶和毛刺,内部密度未见空洞或钙化,邻近胸膜牵拉,病灶呈团块状异常放射性浓颗,右肺门区显示2 个局限性放射性浓聚灶,轮廓清晰;B:患者,女,55 岁,肺窗像示左下肺肿物影,约27 mm×26 mm×37 mm,边缘欠清,密度不均,少许毛刺,强化明显,无空洞形成,肿物远满见斑片状条索状影,左上肺舌段及右中肺见少许斑片状阴影。纵隔窗显示纵淋巴结肿大明显,融合成团,最大直径约50 mm,纵隔大血管形态走行正常。 胸腔无积液,左侧胸膜局部增厚,双侧胸廓对称,骨性胸廓未见破坏
图3 肺淋巴上皮瘤样癌患者组织病理表现 A:肿瘤呈集团状排列,细胞胞界不清,细胞核呈卵圆形梭形,间质大量淋巴细胞、浆细胞浸润;B:肿瘤细胞呈巢状排列,周边伴淋巴组织增生,细胞异型性明显,胞浆丰富偏嗜碱,细胞核增大,核仁明显
1
Nicholson AG,Tsao MS,Beasley MB,et al.The 2021 WHO classification of lung tumors: impact of advances since 2015[J].J Thorac Oncol,2022,17(3): 362-387.
2
韩宝惠.中华医学会肺癌临床诊疗指南(2022 版)[J].中华肿瘤杂志,2022,44(6): 457-490.
3
Liang Y,Wang L,Zhu Y,et al.Primary pulmonary lymphoepitheliomalike carcinoma: fifty-two patients with long-term follow-up [J].Cancer,2012,118(19): 4748-4758.
4
Chen JW,Dhahbi J.Lung adenocarcinoma and lung squamous cell carcinoma cancer classification,biomarker identification,and gene expression analysis using overlapping feature selection methods[J].Sci Rep,2021,11(1): 13323.
5
Nakamura H,Sakai H,Kimura H,et al.Difference in postsurgical prognostic factors between lung adenocarcinoma and squamous cell carcinoma[J].Ann Thorac Cardiovasc Surg,2017,23(6): 291-297.
6
Kawase A,Yoshida J,Ishii G,et al.Differences between squamous cell carcinoma and adenocarcinoma of the lung: are adenocarcinoma and squamous cell carcinoma prognostically equal? [J].Jpn J Clin Oncol,2012,42(3): 189-195.
7
Meng F,Zhang L,Ren Y,et al.The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates[J].J Cell Physiol,2019,234(7): 10918-10925.
8
Lin HT,Liu FC,Wu CY,et al.Epidemiology and survival outcomes of lung cancer: a population-based study[J].Biomed Res Int,2019,2019: 8148156.
9
Grinberg RD,Refaely Y,Cohen LB,et al.Lung cancer in israel[J].J Thorac Oncol,2020,15(4): 493-498.
10
Corrales L,Rosell R,Cardona AF,et al.Lung cancer in never smokers:The role of different risk factors other than tobacco smoking[J].Crit Rev Oncol/Hematol,2020,148: 102895.
11
Zang R,Shi JF,Lerut TE,et al.Ten-year trends of clinicopathologic features and surgical treatment of lung cancer in China[J].Ann Thorac Surg,2020,109(2): 389-395.
12
Huang CJ,Chan KY,Lee MY,et al.Computed tomography characteristics of primary pulmonary lymphoepithelioma-like carcinoma[J].Br J Radiol,2007,80(958): 803-806.
13
Ma H,Wu Y,Lin Y,et al.Computed tomography characteristics of primary pulmonary lymphoepithelioma-like carcinoma in 41 patients[J].Eur J Radiol,2013,82(8): 1343-1346.
14
Sharma A,Fidias P,Hayman LA,et al.Patterns of lymphadenopathy in thoracic malignancies[J].Radiographics,2004,24(2): 419-434.
15
丁小辉,陈本宝,陈雅青.多层螺旋CT 检查对原发性肺淋巴上皮瘤样癌的诊断价值分析[J].中国现代医生,2023,61(18):57-60.
16
Han AJ,Xiong M,Gu YY,et al.Lymphoepithelioma-like carcinoma of the lung with a better prognosis.A clinicopathologic study of 32 cases[J].Am J Clin Pathol,2001,115(6): 841-850.
17
Huang CJ,Chan KY,Lee MY,et al.Computed tomography characteristics of primary pulmonary lymphoepithelioma-like carcinoma[J].Br J Radiol,2007,80(958): 803-806.
18
Ma H,Wu Y,Lin Y,et al.Computed tomography characteristics of primary pulmonary lymphoepithelioma-like carcinoma in 41 patients[J].Eur J Radiol,2013,82(8): 1343-1346.
19
Ho JC,Wong MP,Lam WK.Lymphoepithelioma-like carcinoma of the lung[J].Respirology,2006,11(5): 539-545.
20
Chang YL,Wu CT,Shih JY,et al.New aspects in clinicopathologic and oncogene studies of 23 pulmonary lymphoepithelioma-like carcinomas[J].Am J Surg Pathol,2002,26(6): 715-723.
21
Wu YX,Zhang WL,Wang TM,et al.Genomic landscapes of Epstein-Barr virus in pulmonary lymphoepithelioma-like carcinoma[J].J Virol,2022,96(4): e0169321.
22
鲍军芳,魏新华,江新青.原发性肺淋巴上皮瘤样癌的CT 表现:附14 例报告及文献复习[J].中国CT 和MRI 杂志,2016,14(11): 60-62.
23
尹文娟,苏 丹,谭蔚泓.淋巴上皮瘤样癌分子病理研究进展[J].中国临床新医学杂志,2021,9(14): 845-851.
24
Lin CY,Chen YJ,Hsieh MH,et al.Advanced primary pulmonary lymphoepithelioma-likecarcinoma:clinicalmanifestations,treatment,and outcome[J].J Thorac Dis,2017,9(1): 123-128.
25
Li QW,Qiu B,Hu WM,et al.Plasma Epstein-Barr virus deoxyribonucleic acid copy number predicts disease progression in stage Ⅰ-Ⅱpulmonary lymphoepithelioma-like carcinoma [ J].Front Oncol,2020,10: 1487.
26
Hong HZ,Li JK,Zhang JT,et al.Neoadjuvant immunotherapy in patients with pulmonary lymphoepithelioma-like carcinoma[J].Lung Cancer,2023,181: 107-220.
27
Wu Z,Xian X,Wang K,et al.Immune checkpoint blockade therapy may be a feasible option for primary pulmonary lymphoepitheliomalike carcinoma[J].Front Oncol,2021,11: 626566.
28
Zhong YM,Chen J,Jiang J,et al.Plasma EBV quantification is associated with the efficacy of immune checkpoint blockade and disease monitoring in patients with primary pulmonary lymphoepithelioma-like carcinoma [J].Clin Transl Immunology,2024,13(6): e1515.
29
Zou QH,Liu H,Huang CW,et al.Efficacy and safety of gemcitabine and capecitabine combination for patients with previously treated advanced primary pulmonary lymphoepitheliomalike carcinoma: a retrospective single-arm cohort study[J].Transl Lung Cancer Res,2023,12(1): 96-108.
30
Weng W,Sheng W,Wang L.Human papillomavirus-associated lymphoepithelioma-like carcinoma of the anal canal: a case report and literature review [J].Front Med (Lausanne),2021,8:766960.
31
Pazos M,Eze C,Kahnert K,et al.Novel multimodal management of post-partum synchronous metastatic pulmonary EBV-associated lymphoepithelioma-like carcinoma ( LELC)-a case report [ J].Diagnostics (Basel),2021,11(11): 2072.
32
Zhong YM,Yin K,Chen Y,et al.PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma[J].Front Immunol,2022,13: 951817.
33
Wang L,Lin Y,Cai Q,et al.Detection of rearrangement of anaplastic lymphoma kinase (ALK) and mutation of epidermal growth factor receptor (EGFR) in primary pulmonary lymphoepithelioma-like carcinoma[J].J Thorac Dis,2015,7(9): 1556-1562.
34
Liu Q,Ma G,Yang H,et al.Lack of epidermal growth factor receptor gene mutations in exons 19 and 21 in primary lymphoepithelioma-like carcinoma of the lung[J].Thorac Cancer,2014,5(1): 63-67.
35
Xie C,Xu X,Wu B,et al.Primary pulmonary lymphoepitheliomalike carcinoma in non-endemic region: A case report and literature review[J].Medicine (Baltimore),2018,97(8): e9976.
36
Kim C,Rajan A,DeBrito PA,et al.Metastatic lymphoepitheliomalike carcinoma of the lung treated with nivolumab: a case report and focused review of literature[J].Transl Lung Cancer Res,2016,5(6): 720-726.
37
Liu Y,Long L,Liu J,et al.Case report:anlotinib reverses nivolumab resistance in advanced primary pulmonary lymphoepithelioma-like carcinoma with FGFR3 gene amplification[J].Front Oncol,2021,11: 749682.
[1] 丁科, 张亚琼, 刘杰, 邓莉平, 张永喜, 熊勇. 获得性免疫缺陷综合征相关淋巴瘤患者的临床特征及生存状况的变化趋势[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 278-284.
[2] 杨柯佳, 孙琦, 瞿伟丰, 翁鸢, 崔启辰, 李金友. Flex-3D 胸腔镜肺叶切除术在非小细胞肺癌中的临床应用[J/OL]. 中华肺部疾病杂志(电子版), 2025, 18(01): 62-67.
[3] 谢鹏飞, 陈佳, 张晓东, 张春荣, 许峰. 肺叶气肿比值预测NSCLC 电视胸腔镜肺叶切除术后持续性漏气的临床分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(06): 907-912.
[4] 张卫锋, 张天翼, 赵正维, 王海强, 尹逊亮. VE /VCO2 斜率对肺癌肺叶切除术后心血管并发症的预测意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 725-730.
[5] 杨轲, 丁增巴姆, 马静, 李盼盼, 陈婷. 全程无缝隙肺康复训练在单孔胸腔镜肺叶切除术中的临床应用[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 801-804.
[6] 张礼江, 沈玲佳, 施我大. 倾向性评分匹配分析奥希替尼对晚期NSCLC 预后的影响[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 820-822.
[7] 任甜甜, 张玉慧, 祁玲霞, 朱梅冬, 胡佳. 多学科疼痛管理对胸腔镜肺叶切除术后胸痛及应激反应的影响分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 630-633.
[8] 吕欣谕, 李雯, 王娟侠, 邹维, 王艳, 雷杰. 围手术期肺康复训练在胸腔镜肺叶切除术中疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(02): 256-259.
[9] 赵婷静, 王义凯, 潘华光, 邹敏, 李东戈. 胸腔镜下肺叶切除术手术期低体温的危险因素分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(01): 115-118.
[10] 刘一鸣, 温佳新, 赵恺, 薛志强. ⅢA 期肺腺癌新辅助治疗后胸腔镜右肺中下叶切除术[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(05): 311-313.
[11] 张金珠, 梅世文, 孙金峰, 胡刚, 邱文龙, 李国利, 汪欣, 王锡山, 汤坚强. 原发结直肠癌超系膜切除术后患者的生存危险因素分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(03): 197-204.
[12] 葛雪梅. SOX与mFOLFOX6化疗方案对晚期胃癌的疗效与安全性[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(01): 67-71.
[13] 蔡剑桥, 蒋雷. 单孔胸腔镜与开胸双袖式肺叶切除治疗非小细胞肺癌对比[J/OL]. 中华胸部外科电子杂志, 2024, 11(04): 225-230.
[14] 沈海锋, 吕方伊, 顾海华, 常志博, 陈盈, 王苹莉, 吴祖群, 邱福铭, 姚杰, 范军强. 局部进展期肺癌新辅助治疗后胸腔镜袖式肺叶切除术——浙江大学医学院附属第二医院2014—2023年56例回顾性分析[J/OL]. 中华胸部外科电子杂志, 2024, 11(03): 158-166.
[15] 傅林海, 赵俊俊, 丁剑毅, 杨露萍, 王彬, 魏德胜, 喻光懋. 亚肺叶切除术后迟发性纵隔气肿机制[J/OL]. 中华胸部外科电子杂志, 2024, 11(01): 62-66.
阅读次数
全文


摘要